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ABSTRACT
Tissue plasminogen activator, tPA, is a thrombolytic agent for treatment of the brain or myocardium infarction. Clot lysis assay
is a functional determination method of tPA described in the pharmacopeia. However, the accuracy of clot lysis assay is insufficient because the lysis-time is not determined by the end-point detection. Therefore, an alternative analytical method for the postmarketing quality survey of tPA pharmaceutical formulations is needed. This study was aimed to establish a rapid, precise and costsaving analytical method for tPA routine test. We have compared methods of capillary zone electrophoresis (CZE), size-exclusion
high performance liquid chromatography (SE-HPLC), in vitro clot lysis, enzyme-linked immunosorbent assay (ELISA), and chromogenic substrate assay for the evaluation of recombinant tPA drug products. The results showed that S-2288TM, as substrate of
chromogenic assay for tPA, exhibited a good linear relationship at tPA concentration of 5-50 µg/mL (correlation coefficient: 0.9988).
The intraday precision ranged between 0.5% - 4.3%. Results obtained from our comparative study, suggested that the chromogenic
substrate assay is among the best for tPA assay. The features of precision, rapidity and inexpensiveness of this method are suitable
for a routine test for tPA in pharmaceutical formulations.
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INTRODUCTION
Tissue plasminogen activator (tPA) is a polypeptide consisting of 527 amino acid residues with relative
molecular mass of 59,050 Dalton without consideration
of the carbohydrate moieties attached at positions Asn
117, Asn 184 and Asn 448. The total relative molecular mass is approximately 65,000 Dalton. tPA binds to
fibrin clots and activates plasminogen, leading to the
generation of plasmin and the degradation of fibrin clots
or blood coagulates (1). Clinically, tPA has deemed as a
major therapeutic thrombolytic agent for the treatment of
myocardial infarction, and is also approved for the treatment of ischaemic stroke. The clarification of patenting
issues has been seen nowadays, resulting in a single therapeutic product of full length natural tPA in the market
place, produced by two manufactures (2). Since the
patents of most therapeutic proteins have expired, and the
first biosimilar product has already been approved in the
market (3), the quality compliance of those products from
non-brand-name manufacturers becomes a critical issue.
Potency assay of tPA provided in the pharmacopeia
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monograph of alteplase (1,4) was clot lysis assay. However,
considering the purpose of routine test, a rapid, precise,
and inexpensive method would be demanded and built
to analyze tPA directly in pharmaceutical formulations.
This study was aimed to compare the reference method
(clot lysis), size-exclusion high performance liquid chromatography (SE-HPLC), capillary zone electrophoresis
(CZE), enzyme-linked immunosorbent assay (ELISA)
and chromogenic substrate assay, and employ a suitable
method for routine testing intent.

MATERIALS AND METHODS
I. Materials and Reagents
Tenectaplase reference standard and commercial
product, Metalyse®, were obtained from Boehringer Ingelheim (Germany), tPA International Standard
(98/714) including approximately 20 µg tPA and 5 mg
human albumin from National Institute for Biological
Standards and Control (UK), plasminogen, tPA, arginine, phosphoric acid, and polysorbate 20 from Sigma
(USA), human thrombin and fibrinogen from Calbiochem
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(Germany), molecular weight standards from Bio-Rad
Laboratories (USA). The water used was Milli-Q grade
(Millipore, USA). In the following analytical methods,
standards (Tenectaplase reference standard) and drug
product (Metalyse®) were prepared in serial dilution
with buffer or water to conduct linearity, range, precision, and accuracy (or recovery) test. Placebo solution
consisting of 522 mg arginine, 164 mg phosphoric acid
and 4 mg polysorbate 80 was dissolved in 10 mL water.
Individual testing sample concentrations were described
in each testing method.
II. In Vitro Clot Lysis
The potency of tenectaplase was determined by
comparing its ability to activate plasminogen to form
plasmin with the same capacity of a reference preparation
calibrated in International Units. The formation of plasmin was measured by the determining the lysis time of a
fibrin clot in given conditions. Testing procedures were
as followed: add 600 µL plasminogen-fibrinogen (1:50,
v/v) mixture solution to each cuvette, add 60 µL thrombin, add 60 µL standard or sample solution, mix well
and gently, read the absorbance at 340 nm, and record
the time (second) when the end point (OD340 < 0.03 and
∆ OD340 < 0.003) was reached. Assay buffer was 0.06
M phosphate buffer/0.02% (w/v) NaN3/0.01% (v/v) Tween
80. Assay range was performed from 0.4 to 1.2 µg/mL.
The precision was performed on three different concentrations (0.6, 0.8, and 1.0 µg/mL).
III. Chromogenic Substrate Assay
Coaset® S-2288TM tPA kit for determining the activity of tPA was purchased from Chromogenix-Instrumentation Laboratory SpA (Italy). The structure of S-2288
was H-D-Ile-Pro-Arg-pNA•2HCl. The tPA could induce
dissociation of p-nitroaniline ( pNA), and its activity was
thus determined by the rate at which pNA is released.
The formation of pNA could be followed spectrophotometrically at 405 nm. The procedure was modified from
original insert: for each well of 96-well plate, add Tris
buffer 50 µL, sample or standard 50 µL, and S-2288 50
µL, put in 37°C incubator for 3 minutes. Then, add 50
µL stop solution (20% acetic acid) and read by ELISA
reader. Assay range was performed from 5 to 50 µg/
mL. For determining the tPA only or tPA with albumin
(tPA International Standard), intra-day precision was
performed on three different concentrations (15, 25, and
35 µg/mL). The accuracy of the method was provided by
spiking various concentrations of tPA (15, 25, and 35 µg/
mL) into the placebo solution.
IV. Size-Exclusion High Performance Liquid Chromatography (SE-HPLC)
The SE-HPLC analysis was performed using a GL

Sciences HPLC pump with an absorbance detector. A
TSK G2000 SWXL column (7.8 mm × 300 mm i.d., 5
µm, from Tosoh, Japan) was used. Chromatographic data
were calculated using a Shiunn Haw computing integrator, SISC v4.0 software. The mobile phase consisted of
120 mM ammonium sulfate containing 10% 2-propanol
was adjusted to pH 7.3. The flow rate was 1.0 mL/min,
the detecting wavelength was 280 nm, and the injection
volume was 20 µL. Assay range was performed from
100 to 500 µg/mL. Intra-day and inter-day precision
were performed on three different concentrations (200,
300, and 400 µg/mL). The accuracy of the method was
provided by spiking various concentrations of tPA (100,
200, and 300 µg/mL) into the placebo solution.
V. Capillary Zone Electrophoresis (CZE)
An Agilent G1600A CE system (Germany) was
equipped with UV-VIS detector (photodiode array, 190600 nm), cassette temperature control (4-60°C), and ChemStation software. The uncoated fused-silica capillary (58.5
cm × 50 µm i.d., 50 cm to detector, from Polymicron, USA)
was used with the CZE separation buffer consisted of 100
mM boric acid/40 mM LiCl, pH 5.0, capillary temperature
of 25°C, and detector set at 214 nm. Sample was pressureinjected for 10 sec and the applied voltage was set at 20
kV across the capillary. Assay range was performed from
20 to 100 µg/mL. Intra-day and inter-day precision were
performed on three different concentrations (40, 60, and
80 µg/mL). The accuracy of the method was provided by
spiking various concentrations of tPA (40, 60, and 80 µg/
mL) into the placebo solution.
VI. Enzyme-linked Immunosorbent Assay (ELISA)
Coaliza® ELISA Kit for tPA was purchased from
Chromogenix-Instrumentation Laboratory SpA (Italy).
Microplate wells coated with a monoclonal anti-tPA antibody were used to capture tPA in the sample. A second
antibody, conjugated to horse-radish peroxidase (HRP),
was added. After incubation and removal of untreated
conjugate, enzyme substrate (tetramethylbenzidine,
TMB) was added. Incubation with enzyme substrate
produced a blue color, which turned yellow when the
reaction was stopped by adding sulphuric acid. The
absorbance at 450 nm was then read with ELISA reader
(MRXII, Dynex Technologies, USA). Assay range was
performed from 0 to 15 ng/mL.

RESULTS AND DISCUSSION
I. In Vitro Clot Lysis
The standard curve of tPA analyzed by in vitro
clot lysis was established by plotting the Log second
(y) versus Log concentration of tPA (x). The regression



9.752

8.419

6.709

11.859

5.685

equation was y = -0.735x + 4.4806 (r2 = 0.9888). The
satisfactory linearity ranged from 0.4 µg/mL (0.08 U/mL)
to 1.2 µg/mL (0.24 U/mL). However, several reagents
used in the method were extremely expensive. In addition, the precision and repeatability were not satisfying
enough (RSD 5.3-9.8%).
Clot lysis is a standard method. Before testing, the
protein contents of samples must be determined. In a
collaborative study for establishment of tPA international
standard, several laboratories conducted their in-house
developed methods rather than this pharmacopeia adopted standard method (2).
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II. Chromogenic Substrate Assay
The chromogenic substrate assay was carried in
96-well plate and finished around one hour. The results
showed that the linearity was much better than clot lysis
and detection range (ranging from 5 µg/mL to 50 µg/
mL of tPA) was also acceptable. The regression equations obtained for tPA only and tPA with bovine serum
albumin were y = 0.0165x – 0.0156 (r2 = 0.9966) and y =
0.0148x + 0.0245 (r2 = 0.9952), respectively. In addition,
the RSD of intra-day precision showed 0.5%- 4.3% (Table
1) and it was within acceptable criteria (< 5%).
tPA is one of serine proteases. Several chromogenic
substrates could be used in analysis of tPA. S-2251 was
one substrate of plasmin used for determining tPA activity, which has been reported and measured in absolute
units (5,6). The principle was the same as the clot lysis
assay. However, it was an indirect method. In this study,
a commercial available substrate S-2288 was introduced.
tPA directly catalyzed the S-2288 to pNA. The data was
read by ELISA reader and the loading time control of
samples or reagents was a critical step in the assay.

0

IV. Capillary Zone Electrophoresis (CZE)

0
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Figure 1. The ty pical size-exclusion chromatogram of tissue
plasminogen activator, (A) the molecular weight marker: thyroglobin
670 KDa, bovine gamma globulin 158 KDa, chicken ovalbumin
44 KDa, equine myoglobin 17.5 KDa, and vitamin B12 1.35 KDa,
(B) tPA, 300 µg/mL, retention time: 8.044 minute. Detection was
performed at absorbance 280 nm.
Table 1. Intra-day and Inter-day precision of tPA determined by
chromogenic substrate assay, SE-HPLC, and CZE
Theoretical
conc.
(µg/mL)
Chromogenic
Intra-day
substrate
(tPA without
assay
albumin)

Intra-day
(tPA with
albumin)

III. Size-Exclusion High Performance Liquid Chromatography (SE-HPLC)
The ideal column, TSK G2000 SWXL, for protein
separation was introduced. The chromatogram was
shown in Figure 1. The data showed excellent linearity
(r2 >0.999) and reproducibility ranging from 100 µg/mL
to 500 µg/mL of tPA concentration. Furthermore, the
RSD of intra-day and inter-day precisions was 0.3-1.8%
(Table 1), the recoveries of spiked tPA of 100-300 µg/mL
were 98.9-103.5%, and CV value was 0.4-2.0% (data not
shown). However, the resolution of main peak was interfered with human serum albumin, a common excipient
in pharmaceutical formulation (e.g. the tPA international
standard including 20 µg tPA and 5 mg albumin).
The main purpose of SE-HPLC was impurity determination of reduced tPA, monomer and dimer aggregate.
The protein content (specific activity) could not reflect
the real potency.
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(A)

SE-HPLC

Intra-day

Inter-day

CZE

Intra-day

Inter-day

Actual conc.
RSD (%)
Mean ± SD
(n = 3)
(µg/mL)

15.0

16.6 ± 0.6

3.9

25.0

26.2 ± 1.0

3.7

35.0

36.0 ± 0.4

1.0

15.0

16.8 ± 0.7

4.3

25.0

25.9 ± 0.7

2.8

35.0

36.2 ± 0.2

0.5

200

196.6 ± 2.2

1.12

300

307.7 ± 1.0

0.34

400

410.8 ± 2.5

0.61
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40
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60

60.1 ± 1.7

2.75

80

79.9 ± 1.5

1.92
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4.75

60

60.2 ± 1.3

2.20

80

80.7 ± 1.5

1.86
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Figure 2. The typical capillary zone electrophoresis of tissue plasminogen activator, (A) blank, (B) tPA 20 µg/mL only, (C) Bovine Serum
Albumin 5 mg/mL only.

The CZE result showed good linearity (r2 > 0.998)
and reproducibility ranging from 20 µg/mL to 100 µg/
mL of tPA concentration (data not shown). The RSD of
intra-day and inter-day precisions was 1.9-4.8% (Table
1), which was higher than SE-HPLC. Moreover, the CZE
result showed good resolution of tPA and albumin (Figure
2) in the tPA International standard.
Capillary zone electrophoresis or capillary isoelectric focusing (cIEF) for tPA analysis have been developed
by several laboratories (7-9). Compared with SE-HPLC,
the advantage of CZE method was to separate the albumin from tPA in pharmaceutical formulation. CZE also
showed low sample loading, low solvent consumption,
suitable separation of cations, anions and neutrals, and
was much more powerful in drug development screening.
V. Enzyme-Linked Immunosorbent Assay (ELISA)
The results showed very high sensitivity and good
linearity (r2 > 0.988) ranging from 2.5 ng/mL to 15 ng/mL
of tPA concentration (data not shown). ELISA is a rapid
method for identification and quantitation of tPA(10). Most
commercial ELISA kits are available. ELISA was much
suitable for routine or clinical use. However, the quantitation could not reflect the real biological activity and the
result would also be non-identical if different anti-tPA
epitopes were used.
VI. Comparison of Analytical Methods Studied

A comparative analysis of five methods described
above showed various precision (Table 2). The clot lysis
method adopted by EP and USP, was used as a reference method. It was used to characterize the thrombolytic cascade activity and showed high specificity, but the
reagent cost was high and the reproducibility was poor.
Chromogenic substrate assay operated by substrate, S2288, which was suitable for tPA and other serine proteases, showed good accuracy, good reproducibility, time
saving, and low cost, but the specificity was less than clot
lysis. The bioactivity of tPA could be tested by the above
two methods. The instrumental analysis such as SEHPLC and CZE showed excellent accuracy, reproducibility, and impurity determination, but the protein content
could not reflect the real bioactivity and it showed relative low specificity (retention time only). ELISA utilizing antigen-antibody reaction showed the automatic
feature, excellent sensitivity, and medium specificity, but
the bioactivity and interferences were its main problems.
Overall, the time courses for one 96-well plate manipulated in chromogenic substrate assay and ELISA were
about 1 and 4.5 hours, respectively. The time consumption for any other three methods was more than 6 hours.

CONCLUSIONS
For improving accuracy and precision, five methods
have been applied for measuring the activity or content of
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Table 2. The comparison of analytical methods for determination of tPA
Clot lysis

Chromogenic
substrate assay

SE-HPLC

Capillary
electrophoresis

ELISA

High

Medium

Low

Low

Medium

0.4~1.2

5~50

100~500

20~100

0.0025~0.015

Linearity (r )

0.9888

0.9952

0.9994

0.9979

0.9888

Accuracy (Recovery)

N/A*

RSD< 10%

RSD< 2 %

RSD< 10%

N/A*

Reproducibility (RSD)

<10 %

<5%

<2%

<5%

N/A*

> 6 hours

> 1 hour

> 6 hours

> 6 hours

> 4. 5 hours

High

Low

Medium

Medium

Medium

Specificity
Range (µg/mL)
2

Time course (One plate or 20 tests)
Total cost
*

Not-Available

tPA. Based on the results of our study, the chromogenic
substrate assay is the first choice for the assay of bioactivity of tPA in pharmaceutical formulations because of
its rapidity, inexpensiveness, accuracy, and enzymatic
activity testing. SE-HPLC or CZE method could serve
as an alternative choice for a quantitative routine assay of
tPA due to its excellent precision.
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